We analyzed toxicity and efficacy of chemotherapy (CT) or second stem cell transplantation (SCT) and/or immunotherapy defined as stop of immunosuppression (IS) or donor leukocyte infusion (DLI) in 47 patients relapsing with acute leukemia. Ten patients received no treatment and 14 patients were treated with CT only. In 12 patients IS was stopped and three of them received additional CT. Five patients received DLI after CT as consolidation and one patient as frontline therapy. Five patients received a second SCT. Median overall survival after relapse was 2 months for the untreated patients, 2 months for patients receiving CT only, 2 months in patients after cessation of IS, 17 months in DLI treated patients and three months in patients receiving a second SCT. Fourteen patients achieved remission after relapse. Two with CT (2, 2 months), three with SI (3, 19, 19+ months), six with DLI (3, 8, 9, 14, 20, 36 months) and three with second SCT (2, 4, 6 months). Conventional CT was able do re-establish donor hematopoiesis and patients achieving remission showed a significantly better survival than patients with refractory disease. Patients who were brought into remission by DLI or cessation of IS had a significantly better survival than patients who achieved remission with CT alone or a second SCT. We conclude that a selected group of patients achieving remission with regeneration of donor hematopoiesis following CT might benefit from immunotherapy as consolidation. Leukemia (2001) 15, 355-361. 
Introduction
Patients who relapse after allogeneic stem cell transplantation (SCT) have a poor prognosis. A high proportion of them may be considered unfit for further intensive therapy. Standard chemotherapy can result in complete remission (CR) but longterm disease-free survival is unlikely because of high treatment-related toxicity and recurrence of disease.
1,2 A second allograft may cure some patients 3 but transplant-related morbidity and mortality are high with 100 day mortality rates of 25 to 50% and a disease-free survival of 10%. 4, 5 Features considered with poor outcome after second allogeneic SCT include an interval between the procedures of less than 1 year, resistance to reinduction chemotherappy, older age and poor performance score. 6 Cytokines stimulating residual donor hematopoiesis in relapse or suppressing the leukemic clone have been investigated but a stable remission is unlikely. 7, 8 Immunotherapy as cessation of immunosuppression 9, 10 in patients with early post-transplant relapse or cell therapy with donor leukocyte infusion (DLI) 11, 12 can be a promising and less toxic therapy. It may enhance the graft-versus-leukemia efficacy of T cells of donor origin once full chimerism is established. For chronic myeloid leukemia (CML) antigens presented through the minor histocompatibility antigens on host cells are essential to cause response against leukemia. T cells infused from the original donor 13, 14 inhibit the growth from leukemic cells or eradicate them, 15 resulting in remission rates of about 70%. 11, 12 The remission rate for acute myeloid leukemia (AML) and acute lymphatic leukemia (ALL) obtained after cell therapy is less promising 11, 12, 16, 17 if compared with CML. After DLI CR was achieved in around 15% of selected patients with untreated relapse. 11, 12 For acute leukemia the graft-versus-leukemia effect might be weaker or the rapid growth of the leukemic clone exceeds an effective immune response which is usually seen 5 to 6 weeks after DLI. 11, 18 DLI may be more effective if used in CR or minimal residual disease suggesting that reinduction chemotherapy should be administered prior to DLI. Early cell therapy in molecular relapse or DLI as an immunological consolidation in CR after conventional chemotherapy may be another therapeutic option. [19] [20] Here, we analyze the outcome of patients relapsing after an allogeneic SCT treated with either cytotoxic chemo-radiotherapy or with different approaches of adoptive immunotherapy. Since we could previously demonstrate that CD34-positive cells of recipient origin in relapse are targets of alloreactive donor cells whether they are leukemic or not and lack of donor CD34-positive cells is predictive for aplasia, 22, 23 we assessed the hematopoietic chimerism in some patients in relapse as a possible predictor for aplasia and therapeutic response.
Patients and methods

Patient characteristics
Forty-seven patients, 27 female and 20 male with a median age of 32 years with ALL or AML relapsed after allogeneic SCT at our institution between 1989 and November 1999. Their characteristics are shown in Table 1 . The conditioning regimens used for transplantation and protocols for graft-versushost disease (GVHD) prophylaxis were those used at our institution during the time period patients were transplanted. Twenty-two patients were in remission at the time of transplantation and 25 were in relapse or refractory disease. Thirtythree patients received a stem cell graft from human leukocyte antigen (HLA)-identical siblings, 11 from HLA-identical and three from one antigen mismatched unrelated donors. Six patients received peripheral blood stem cells all from related donors and 41 patients had bone marrow cells infused. The median of mononuclear cells infused was 2.5 × 10 8 /kg body weight (b.w.) with a median of 3.3 × 10 6 CD34-positive cells/kg b.w. For GVHD prophylaxis 35 patients received cyclosporin A (CsA) and methotrexate (MTX) according to the Seattle protocol. 24 Two patients were given MTX alone, two CsA and methylprednisolone 25 and eight CsA alone. Thirty patients suffered acute GVHD and chronic GVHD was observed in 12 patients. Acute and chronic GVHD were confirmed by appropriate biopsies and clinically graded as 0-IV for acute and limited or extensive for chronic GVHD, as published elsewhere. 26, 27 Engraftment was seen in all patients between days 9 and 43 after stem cell infusion. Relapse was defined as leukemia recurrence in bone marrow, central nervous system or extramedullary disease confirmed by appropriate aspiration or biopsy. Time from allogeneic SCT to relapse was less than 6 months in 24 patients.
Treatment of relapse
Treatment of relapse was heterogeneous and varied depending on patients condition, age at relapse and time from relapse to allogeneic SCT ( Table 2) .
(1) No treatment: Ten patients received no chemotherapy or hydroxyurea because of poor clinical condition or refusal of any further treatment. Median time from SCT to relapse was 3 months (ranging from 2 to 24 months). (2) Chemotherapy:
Fourteen patients were treated with either fludarabine, cytosine arabinoside (Ara-C) and G-CSF (FLAG) 28 (nine patients with AML and one patient with ALL) or Ara-C and anthracycline-based salvage therapy 29 (three patients with AML) or reinduction therapy according to the GMALL 02 protocol 30 (one patient with ALL). Median time from SCT to relapse was 9 months (range of 2 to 38 months). Three patients were on CsA when relapse was diagnosed and in these patients CsA was continued according to our standard GVHD prophylaxis protocol. The other 11 patients were off CsA at the time of relapse (median time from stop of CsA to relapse: 9 months; range 1 to 22 months). (3) Stop of immunosuppression: In four patients treatment of acute or chronic GVHD was stopped and in eight patients GVHD prophylaxis was discontinued at the time of relapse. Immunosuppression consisted of CsA in nine patients and CsA plus methylprednisolone in three patients. Median time from SCT to relapse was 4 months with a range from 2 to 10 months. One patient with CNS relapse received methotrexate and Ara-C intrathecally and CsA was stopped at the same time. The other patients did not receive reinduction chemotherapy at the time of relapse. (4) DLI: Since 1995 six patients received unmanipulated DLI from the original stem cell donor. All patients were off immunosuppression at the time of relapse. Median time from SCT to relapse was 19 months ranging from 4 to 40 months. Time from cessation of CsA to relapse ranged between 2 and 37 months in these patients. Four patients with AML received reinduction chemotherapy with FLAG and one patient with ALL suffering relapse of central nervous system (CNS) received methotrexate and Ara-C intrathecally. DLI as consolidation was given between 3 and 6 weeks after chemotherapy when recovery of hematopoiesis was observed. One patient in early relapse of Ph-positive ALL received DLI without any chemotherapy. Between 1.4 and 4 × 10 8 CD3-positive cells were infused per kg b.w. Until 1997 patients received 4 weekly infusions of donor leukocytes with a cell dose between 2 and 4 × 10 8 CD3-positive cells/kg b.w. 31 The following patients received only one course of DLI not exceeding 1 × 10 8 CD3-positive cells/kg b.w. (5) Second SCT: A second allograft was offered to five patients who were in good clinical condition but no specific eglibility criteria existed for these patients and the decision was made at the discretion of a senior attending physician. Median time from first SCT to relapse was 16 months, ranging from 10 to 74 months. Two of these patients received Ara-C and anthracycline-based salvage chemotherapy before second allogeneic SCT. No patient received pretreatment with DLI and all patients were off CsA between 6 and 68 months at the time relapse was diagnosed.
Cytogenetic analysis:
In 33 of 47 patients with acute leukemia bone marrow was analyzed for cytogenetic abnormalities according to standard procedures 32 and subjected to trypsin-Giemsa staining. At least 20 metaphases were examined in all cases. For AML cytogenetic abnormalities were defined as favorable, intermediate and adverse as previously described. 33 For ALL the Philadelphia (Ph) translocation t(9;22)(q34;q11) and the t(4,11) were defined as adverse. Out of these 33 patients 15 had unfavorable and 18 favorable or intermediate cytogenetic abnormalities.
Immunological staining and cell sorting:
In seven patients CD3-and CD34-positive cells were analyzed in relapse. For immunological staining CD34-positive cells in the bone mar- row and CD3-positive cells in the blood were incubated at a concentration of 10 7 cells/ml in appropriately diluted MoAb as described. 34 Flow cytometric cell sorting was performed on a FACStar Plus (Becton Dickinson, San Jose, CA, USA) using an argon laser adjusted to an excitation wave length of 488 nm. The purity of each sort ranged from 96% to 100%.
Analysis of variable number of tandem repeats with PCR (VNTR-PCR):
We used a VNTR region within the intron 40 of the van Willebrand factor gene for the distinction between donor and recipient origin of CD34-and CD3-positive cells in two cases of sex matched SCT. PCR and evaluation were performed as described previously. 35 The sensitivity of our PCR method allowed the detection of 5 to 10% of donor cells in the presence of recipient cells and vice versa.
Fluorescence in situ hybridization (FISH) of cytospin preparations:
Differentially labeled X and Y chromosome-specific centromere probes (Vysis, Downers Grove, II, USA) were used in five patients with sex mismatch transplantation. FISH Leukemia analyses were performed on cytospin preparations, each containing up to 10 000 sorted CD34-and CD3-positive cells according to the manufacturer's instructions. The cut-off level (median plus 3 times standard deviations) which was determined on normal controls was 1.6% for the X-and Yspecific probes. 36 At least 200 interphase nuclei per slide were analyzed.
Statistical analyses
Overall survival and disease-free survival for patients relapsing after allogeneic SCT were calculated with the product limit method, according to Kaplan and Meier. 37 Overall survival was calculated from the time of relapse after first allogeneic SCT. The significance of differences between the different risk groups or different treated groups was estimated by the logrank test (Mantel-Cox) and P value Ͻ0.05 was considered to be significant. Data were analyzed as of September 2000. Table 2a and b show treatment modalities and survival after relapse.
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Treatment of relapse after allogeneic SCT and survival
(1) No treatment: Ten patients, six with AML and four with ALL received no treatment or only hydroxyurea because of poor condition or refusal of any further treatment. Median from relapse to death was 2 months (range 1 to 7 months) with 100% disease-related mortality. (2) Chemotherapy: Fourteen patients, 12 with AML and two with ALL received reinduction chemotherapy without any further treatment. Two patients achieved remission. One patient died in CR because of cardiac failure and the other patient relapsed after 2 months. Median survival after relapse was 2 months (range 1 to 7 months). Eleven patients died because of refractory disease or relapse and three patients because of treatment-related toxicity. (3) Stop of immunosuppression: In 12 patients, 10 with AML and two with ALL, immunosuppression was stopped in relapse. Three patients achieved remission and two of them relapsed after 3 and 19 months in CR. One patient with CNS relapse receiving intrathecal chemotherapy achieved CR and CsA was stopped as consolidation therapy. Two patients treated with cessation of immunosuppression as frontline therapy achieved remission without any chemotherapy and one of them is still alive and disease free with limited chronic GVHD 22 months after relapse. Median time from relapse to death was 2 months with a range from 1 to 28 months and all 11 patients died because of relapse or refractory disease. These patients did not receive any further chemotherapy or DLI. (4) Donor leukocyte infusion: Six patients, four with AML and two with ALL received DLI. Five patients received salvage chemotherapy resulting in CR and DLI was given as consolidation cell therapy (Table 2a and b) . One patient with Phpositive ALL received DLI in early relapse without reinduction chemotherapy. In all patients donor leukocytes were well tolerated and no side-effects were seen immediately after infusion. Four of the five patients receiving DLI as consolidation after chemotherapy relapsed between 3 and 36 months. One of them remained in stable remission but died because of respiratory failure due to chronic extensive GVHD of the lung 20 months after DLI. The patient with early relapse of Ph-positive ALL achieved remission but died in molecular remission because of extensive chronic GVHD 9 months after DLI. Median overall survival of the six patients receiving cell therapy was 17 months with a range from 6 to 42 months. Duration of remission exceeding that obtained after allogeneic 
Hematopoietic chimerism in patients in relapse after allogeneic SCT
In seven patients we investigated chimerism of CD3-and CD34-positive cells in relapse (Table 3 ). In five patients with a sex mismatch allograft donor and recipient CD34-and CD3-positive cells were quantified by FISH (patients 1 to 5 in Table 3 ). In two male patients with male donors chimerism of sorted CD34-and CD3-positive cells was analyzed by VNTR-PCR (patients 6 and 7). In relapse CD3-positive cells in the blood were exclusively from donor type. All our patients received a non-T cell-depleted allograft and chimerism was analyzed in early relapse which might explain full donor T cell chimerism. In the patient with ALL suffering CNS but not hematological relapse, CD34-positive cells were exclusively from donor type whereas in the other patients CD34-positive cells of recipient origin were seen at the time of relapse. Standard reinduction chemotherapy was given in five patients with AML and reestablished full donor hematopoiesis with CD34-positive cells of donor type. Patients receiving DLI in CR or with residual donor hematopoiesis did not experience aplasia. One female patient (patient 1a), received DLI in relapse as first line therapy and experienced aplasia. Although the patient received peripheral blood stem cells from her HLA-identical brother she remained aplastic and a recovery of blasts of recipient type was seen. After reinduction chemotherapy full donor chimerism with exclusively male donor hematopoiesis (patient 1b) was achieved and no aplasia was seen after consolidation with DLI. 
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Factors possibly affecting survival in patients relapsing after allogeneic SCT
As seen in Table 4 patients who achieved CR after salvage reinduction chemotherapy had a significantly better survival than nonresponders. Time from SCT to relapse, cytogenetic risk factors, age at first SCT and remission status at first SCT had no prognostic significance.
Overall survival and disease-free survival of patients achieving remission in relapse after allogeneic SCT
Fourteen patient achieved CR after relapse (Table 5) . Nine patients were treated with cell therapy or cessation of immunosuppression and five patients were treated with chemotherapy alone or a second allograft after conditioning therapy. In the group treated with immunotherapy the median duration of disease-free survival was 14 months (range 3 to 36 months). The median overall survival after relapse was 16 months (range 6 to 42 months). In patients treated with chemotherapy alone or with a second allograft after conditioning therapy median disease-free survival was 2 months (range 2 to 6 months). Median overall survival was 4 months( range 2 to 6 months). As seen in Table 5 patients achieving CR after relapse had a significantly better disease-free and overall survival if treated with immunotherapy than patients who Leukemia were treated with chemotherapy alone or who received a second allograft.
Discussion
Allogeneic SCT establishes complete chimerism with donor hematopoiesis in the myeloid and lymphatic lineage.
Here, we show that in patients relapsing after a non-T celldepleted allograft, T cells remain of donor origin whereas recipient-derived hematopoiesis contributes to relapse. Therefore, two therapeutical approaches may be successful to treat relapse of leukemia after an allogeneic SCT. The direct cytotoxic approach by reinduction chemotherapy to suppress the rapid proliferating malignant clone and re-establish residual healthy hematopoietic cells of donor type or the stimulation of the alloreactive T cells by cell therapy or withdrawal of immunosuppression. Once T cell chimerism is established in the recipient alloreactive T cells may suppress cells of host type or even eliminate residual leukemic cells. As a therapeutic effect of immunotherapy is usually seen after 5 to 10 weeks 11, 18 even an effective stimulation of immune-competent cells may not be able to suppress a rapid expansive leukemic clone in relapse. Therefore, a combination of reinduction chemotherapy with consolidation by DLI might be a promising therapeutic approach.
We could re-establish donor hematopoiesis by conventional chemotherapy and CD34-positive cells of exclusively donor type were seen in patients achieving remission 3 to 4 weeks after chemotherapy. If re-establishment of donor hematopoiesis was achieved by conventional reinduction chemotherapy no aplasia was seen. Treatment with alloreactive donor cells in relapse with recipient hematopoiesis or persistence of leukemic blasts from donor type resulted in aplasia. These data confirm our previously published observations in patients relapsing with leukemia at early or late stage of disease 22, 23, 29 and myeloma. 36 Thus, response to standard reinduction chemotherapy may be an important predictor for successful cell therapy. The benefit of additional DLI once remission is achieved is likely as we observed remissions up to 36 months after relapse exceeding first remission after allogeneic SCT. In contrast, duration of remission obtained after chemotherapy is limited if no immunotherapy is given. 1 There are reports where peripheral stimulated blood stem cells are used as cell therapy in relapse after allogeneic stem cell transplantation. 38 An infusion of peripheral stem cells stimulated by G-CSF may not be necessary if reinduction chemotherapy is able to re-establish full donor hematopoiesis. Thus, a patient who achieves remission after chemotherapy may not need additional stem cell support and patients treated with PBSC in relapse not responsive to standard chemotherapy are unlikely to profit from this therapeutic approach. Allogeneic SCT is performed in increasing frequency from volunteer unrelated donors and it is important to evaluate what sort of cell therapy is used in relapse. Reinduction chemotherapy might spare some second stimulation of stem cells in healthy volunteer matched unrelated or related donors and unstimulated mononuclear cells from the original donor should be sufficient to stimulate a graft-versus-leukemia effect. Recently, a better initial response of DLI in unrelated SCT has been shown with a higher response rate after DLI 39 but long-term outcome was still unsatisfactory as of 15 patients with AML only one remained alive in CR 1 year after DLI. We could obtain lasting remissions and survival by combined chemo-and cell therapy after relapse although cure was not achieved. A second therapeutic approach is withdrawal of immunosuppressive therapy in early relapse after allogeneic SCT which resulted in remissions without toxic side-effects. A second allograft is the most intensive and most toxic therapeutic approach. Patients who receive a second allograft and are not in remission at the time of transplantation or who relapse within 1 year have a desperate outcome. 4 Four of five patients received a second allograft in relapse or refractory disease and no stable remission was achieved because of treatment-related deaths or refractory disease. The treatment groups in our study are biased by different therapeutic decisions at the time of relapse. However, if we compare patients achieving CR after relapse with reinduction chemotherapy followed by DLI they showed a significantly better survival than patients who achieved remission by standard chemotherapy alone or second allogeneic SCT. Conventional chemotherapy followed by cell therapy or in specific cases by a second transplant seems to be a reasonable therapeutic procedure. For the future early detection of relapse by molecular monitoring with rapid therapeutic intervention might be a promising approach. The second option would be to define patients who are at high risk of relapse and use cell therapy as prevention once full T cell chimerism is achieved.
